Transplant

A recent study conducted by the University of Cincinnati found that patient outcomes were almost identical for generic and brand-name versions of tacrolimus, a drug used post-transplant to reduce the risk of organ rejection. With more affordable generics now on the market, the study took a closer look at the outcomes of what have often been referred to as narrow therapeutic index medications.

Researchers at the MIRA Research Institute and the Radboud University Nijmegen Medical Center (RUNMC) in the Netherlands recently created a living kidney membrane. To do this, they combined kidney epithelial cells (cells made of protective tissue) with an artificial membrane. Dr. D. Stamatialis led researchers at MIRA and Dr. R. Masereeuw led researchers at RUNMC to publish their shared findings in the scientific journal Acta Biomaterialia. Their research is part of the Bioart project under the auspices of the European Union (EU) Marie Curie Initial Training Networks (ITN).

Studies show that kidneys from deceased donors who had acute injuries (defined as injuries with blood loss that affect the kidney, often sustained in car accidents) are frequently discarded, but could be transplanted with better results than transplants with delayed graft function. (Delayed graft function occurs when a transplanted kidney does not immediately start to function properly and may require some dialysis for a period of time.)